Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2115-2122

  Perez, Edith A ^a   Dueck, Amylou C ^b   McCullough, Ann E ^b   Chen, Beiyun ^c   Geiger, Xochiquetzal J ^a   Jenkins, Robert B ^c   Lingle, Wilma L ^c   Davidson, Nancy E ^d   Martino, Silvana ^e   Kaufman, Peter A ^f   Kutteh, Leila A ^g   Sledge, George W ^h   Harris, Lyndsay N ⁱ   Gralow, Julie R ^j   Reinholz, Monica M ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e Angeles Clinic and Research Institute   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g Oncology Associates of Cedar Rapids   (United States)

^h INDIANA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ YALE UNIVERSITY   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HORMONE RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PTEN PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; FEMALE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; AGED; BIOSYNTHESIS; BREAST NEOPLASMS; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PACLITAXEL; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84886408077     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.2642     Document Type: Article

References (28)

1. Perez EA, Suman VJ, Davidson NE, et al: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497, 2011
2. Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2012
3. Perez EA, Spano JP: Current and emerging targeted therapies for metastatic breast cancer. Cancer 118:3014-3025, 2012
4. Fabi A, Metro G, Di Benedetto A, et al: Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 78:141-149, 2010
5. Mukohara T: Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science 102:1-8, 2011
6. Zhang S, Yu D: PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16:4325-4330, 2010
7. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007
8. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
9. Fujita T, Doihara H, Kawasaki K, et al: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:247-252, 2006
10. Gori S, Sidoni A, Colozza M, et al: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: Correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 20:648-654, 2009
11. Dave B, Migliaccio I, Gutierrez MC, et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-173, 2011
12. O’Brien NA, Browne BC, Chow L, et al: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489-1502, 2010
13. Faratian D, Goltsov A, Lebedeva G, et al: Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 69:6713-6720, 2009
14. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647-1656, 2010
15. Yonemori K, Tsuta K, Shimizu C, et al: Immu-nohistochemical expression of PTEN and phosphor-ylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 26:344-349, 2009
16. Loi S, Michiels S, Lambrechts D, et al: Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. J Clin Oncol 30:8s, 2012 (suppl; abstr 507)
17. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A ran-domised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
18. Perez EA, Jenkins RB, Dueck AC, et al: C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol 29:651-659, 2011
19. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002
20. Herceptin (trastuzumab) package insert. Genentech, San Francisco, CA, May 2008. http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf
21. Sangale Z, Prass C, Carlson A, et al: A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 19:173-183, 2011
22. The Human Protein Atlas.http://www.proteinatlas.org/ENSG00000171862/normal/breast
23. Sakr RA, Barbashina V, Morrogh M, et al: Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18:371-374, 2010
24. Winter JL, Stackhouse BL, Russell GB, et al: Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med 131:767-772, 2007
25. Razis E, Bobos M, Kotoula V, et al: Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128:447-456, 2011
26. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093-1101, 2011
27. Pérez-Tenorio G, Alkhori L, Olsson B, et al: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577-3584, 2007
28. Tolles J, Bai Y, Baquero M, et al: Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 13:R51, 2011